{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-pregnancy-associated/prescribing-information/omeprazole/","result":{"pageContext":{"chapter":{"id":"a4e035b2-17fe-5771-bf7c-e6316042dfea","slug":"omeprazole","fullItemName":"Omeprazole","depth":2,"htmlHeader":"<!-- begin field e9a4c277-a73a-45dc-a7ef-ad1588df0de2 --><h2>Omeprazole</h2><!-- end field e9a4c277-a73a-45dc-a7ef-ad1588df0de2 -->","summary":"","htmlStringContent":"<!-- begin item a13be4cc-0005-4535-983c-53717c3b0daf --><!-- end item a13be4cc-0005-4535-983c-53717c3b0daf -->","topic":{"id":"b8d88ee2-8a69-52eb-9d32-912284197e1f","topicId":"dc0be124-58d0-4024-933f-b2fbd474ded2","topicName":"Dyspepsia - pregnancy-associated","slug":"dyspepsia-pregnancy-associated","lastRevised":"Last revised in April 2017","chapters":[{"id":"60f9996f-609e-58ab-a9f8-6c7592ee178e","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"c2b3abe4-1e96-5b8c-b8d3-09d2cb373103","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"a73c5a28-6104-52d9-800f-46667f547593","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"47b7f91b-c83d-54ef-8574-e76eb372bd2f","slug":"changes","fullItemName":"Changes"},{"id":"4f2d76ee-05fa-5ad6-9f05-94ce8aeea75c","slug":"update","fullItemName":"Update"}]},{"id":"e3b58cd1-dacb-5e2b-83a8-3f22adb3d45e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1f0a7f78-310a-5b31-bfaf-767b6e748abc","slug":"goals","fullItemName":"Goals"},{"id":"9c124ebe-f349-5be6-aceb-708911d511ab","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"8fa88023-a3f6-51d6-9cf0-8e6cafd2a378","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"8bc89572-4ae3-55e9-a17a-dcdf07479f7e","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"1b45fcb4-c387-513f-85da-a5f4d0d06c44","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"45c50037-8ca1-55b5-a6aa-9fda720d7647","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"ee1aafc3-d046-5f55-8326-4f6eea576ad4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a33a561f-20e2-5055-93ea-13e7f9792241","slug":"definition","fullItemName":"Definition"},{"id":"c0a56bee-ebd7-515f-ad7a-e659b803ef4f","slug":"causes","fullItemName":"Causes"},{"id":"43050203-854e-501c-969a-4ef9ca2e693a","slug":"prevalence","fullItemName":"Prevalence"},{"id":"d37ff081-b4e8-5bed-8525-97babc845cc3","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"1e7d1d6b-e749-549b-80e1-505aeae8c3b0","slug":"complications","fullItemName":"Complications"},{"id":"e925ce1f-978f-5f2d-95c4-42e4c5329ba9","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"5b93254f-d6b2-548f-8332-981acee23d8d","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"37e18679-14e0-55e8-9ff3-98ec1f8b4dc8","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"9df83943-7b99-5528-b96d-cf1a3d31e340","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"4d3fcf99-02c1-5ae0-a88f-6ede4299e2e4","fullItemName":"Management","slug":"management","subChapters":[{"id":"7d3d9638-da7b-5e7c-bee8-d2cddbe706f0","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"b7e38fc5-888d-5f8f-b554-d5a6d7c0169e","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"891c5a5d-fe64-5740-8bea-1288bb40fe1d","slug":"antacids-alginates","fullItemName":"Antacids and alginates"},{"id":"60de1b71-33b9-5a85-8db2-22f04ab2568c","slug":"ranitidine","fullItemName":"Ranitidine"},{"id":"a4e035b2-17fe-5771-bf7c-e6316042dfea","slug":"omeprazole","fullItemName":"Omeprazole"}]},{"id":"dd43a335-6bef-54d0-b721-23c0399cbca6","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"1b228dcd-0e8b-5fbb-8dd4-a3307cb52b3d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"436e8102-5b89-580c-8c58-6895cda4ae97","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"178fa7df-fb25-5bda-bd69-1cebda0cbbf0","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"09c54592-0d38-52dc-b0b8-33b5dea6130e","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ad6eb72f-398b-5f96-bd8d-c07cdd9bd570","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"56db1aa0-6292-5b08-9b08-7addf535756d","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"f687e796-c2d6-5737-86fe-8977f4ba5257","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"b7e38fc5-888d-5f8f-b554-d5a6d7c0169e","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"7c184041-4b52-5fd2-a9ee-cd38eec09918","slug":"dosage","fullItemName":"Dosage","depth":3,"htmlHeader":"<!-- begin field 04c17184-3d7b-4bf3-b61f-a73500a101ef --><h3>What dosage of omeprazole should I prescribe?</h3><!-- end field 04c17184-3d7b-4bf3-b61f-a73500a101ef -->","summary":"","htmlStringContent":"<!-- begin item 35d9051b-6199-4705-a51e-a73500a10033 --><!-- begin field f8d48570-7591-46a1-9471-a73500a101ef --><ul><li>CKS recommends the use of standard doses of omeprazole as used for other people with acid reflux disease, as there is an absence of evidence on dosage in pregnancy from controlled trials. For gastro-oesophageal reflux disease:<ul><li>The recommended dose is 20 mg once daily, however, some people may have adequate relief of symptoms using 10 mg daily, so consider individual dose adjustment [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">ABPI Medicines Compendium, 2017</a>]. In pregnancy, use the smallest effective dose [<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">BNF 72, 2016</a>].</li></ul></li></ul><!-- end field f8d48570-7591-46a1-9471-a73500a101ef --><!-- end item 35d9051b-6199-4705-a51e-a73500a10033 -->","subChapters":[]},{"id":"390e21de-5c1d-59f5-8c0c-278891c78707","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field bdeb75f0-2b6b-41ae-8c2e-a73500a11eef --><h3>What contraindications and cautions are associated with omeprazole?</h3><!-- end field bdeb75f0-2b6b-41ae-8c2e-a73500a11eef -->","summary":"","htmlStringContent":"<!-- begin item 022ee64f-b5bd-476d-b2e4-a73500a11da6 --><!-- begin field 19c26b95-9053-43cf-ac35-a73500a11eef --><ul><li>Do not prescribe omeprazole if the person has a history of:<ul><li>Hypersensitivity to the drug or its excipients.</li><li>Features suggesting malignancy — exclude malignancy before prescribing, as omeprazole can mask the symptoms of gastric cancer.</li></ul></li><li>Prescribe omeprazole with caution for people:<ul><li>With reduced body stores of vitamin B12 — omeprazole may reduce absorption of vitamin B12.</li><li>At risk of osteoporosis — proton pump inhibitors may increase the risk of hip, wrist, and spine fractures (especially at high doses or if the duration of treatment is long).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field 19c26b95-9053-43cf-ac35-a73500a11eef --><!-- end item 022ee64f-b5bd-476d-b2e4-a73500a11da6 -->","subChapters":[]},{"id":"643a99b4-3664-5937-a360-da0cb4043107","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 29ffe82f-c2de-46b4-8b3f-a73500a13f32 --><h3>What adverse effects are associated with omeprazole?</h3><!-- end field 29ffe82f-c2de-46b4-8b3f-a73500a13f32 -->","summary":"","htmlStringContent":"<!-- begin item 160869ad-740e-4be0-be20-a73500a13dbe --><!-- begin field 61c42312-6f10-45b5-a17d-a73500a13f32 --><ul><li>Gastrointestinal adverse effects (such as nausea, vomiting, constipation, and diarrhoea) can occur with omeprazole. Because of their acid-suppressing effect, proton pump inhibitors may increase the risk of <em>Clostridium difficile </em>and other gastrointestinal infections.</li><li>Other less common adverse effects include:<ul><li>Headache.</li><li>Dizziness.</li><li>Dry mouth, altered taste, stomatitis.</li><li>Increased risk of fractures (particularly in those taking omeprazole at high doses or for long periods of time).</li><li>Blood disorders (for example leucopenia, thrombocytopenia, pancytopenia).</li><li>Hepatitis, jaundice.</li><li>Depression, confusion, hallucinations.</li><li>Paraesthesia, myalgia, arthralgia.</li><li>Electrolyte disturbances such as hyponatremia and hypomagnesaemia.</li><li>Skin conditions, including:<ul><li>Rash, pruritus, photosensitivity, Stevens-Johnson syndrome.</li><li>Subacute cutaneous lupus erythematosus — has been rarely reported in people taking proton pump inhibitors and can occur weeks, months, or years after exposure. Consider this as a diagnosis if the person develops lesions (particularly on sun-exposed areas of the skin) and arthralgia. It may be necessary to stop omeprazole treatment.</li></ul></li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field 61c42312-6f10-45b5-a17d-a73500a13f32 --><!-- end item 160869ad-740e-4be0-be20-a73500a13dbe -->","subChapters":[]},{"id":"0f21258b-f507-5467-86bd-16ceb2d9ec8f","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 360aff3a-70e0-466f-8778-a73500a1867f --><h3>What are the drug interactions with omeprazole?</h3><!-- end field 360aff3a-70e0-466f-8778-a73500a1867f -->","summary":"","htmlStringContent":"<!-- begin item 95b5eeff-311c-4989-b5ba-a73500a1853b --><!-- begin field 9ee834f8-55b6-4d3c-9523-a73500a1867f --><ul><li>Drug interactions with omeprazole include:<ul><li>Cilostazol — plasma concentration is increased with concurrent omeprazole use.</li><li>Clopidogrel — the antiplatelet effect of clopidogrel is reduced with omeprazole use.</li><li>Escitalopram (and probably citalopram) — levels are increased by 50% with omeprazole use. Monitor for SSRI adverse effects (for example nausea, diarrhoea, dry mouth).</li><li>Coumarin anticoagulants — the anticoagulant effect may be enhanced.</li><li>Phenytoin — metabolism is decreased, which may increase exposure to phenytoin. Monitor plasma phenytoin levels for the first two weeks after omeprazole is started and after any dose changes.</li><li>Rilpivirine — plasma concentration of rilpirivine is reduced by concurrent use with omeprazole.</li><li>Protease inhibitors, including:<ul><li>Saquinavir — the plasma concentration of saquinavir is increased by concurrent use with omeprazole.</li><li>Tipranavir — the plasma concentration of omeprazole is reduced.</li><li>Atazanavir — proton pump inhibitors decrease plasma levels.</li></ul></li><li>Itraconazole and ketoconazole — proton pump inhibitors decrease absorption of these drugs.</li><li>Methotrexate — excretion of methotrexate may be reduced with concurrent use of proton pump inhibitors, leading to increased levels and increased risk of toxicity.</li><li>Inducers of CYP2C19 and CYP3A4 (for example rifampicin and St John's wort) — omeprazole metabolism may be increased by these drugs, leading to lower serum levels.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">BNF 72, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">Preston, 2016</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-pregnancy-associated/references/\">ABPI Medicines Compendium, 2017</a>]</p><!-- end field 9ee834f8-55b6-4d3c-9523-a73500a1867f --><!-- end item 95b5eeff-311c-4989-b5ba-a73500a1853b -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}